Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Industry Trends
  • Published:

Biotechnology valuation

Nature Biotechnology volume 15, pages 813–814 (1997)Cite this article

The guiding principles behind the financial exercise that some view as an art form.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. The authors state that the descriptions and views given in the present article are their own personal views and descriptions and do not represent the formal opinions and positions of their employers. No warranties are given or made, and anyone wishing to apply the methods above should consult professional advisors.

  2. Copeland, T. and Koller, T. Murrin, J. 1996. Measuring and managing the value of companies. Second Edition. John Wiley & Sons, Inc. NY.

    Google Scholar 

  3. Fusfeld, A.R. 1996. Placing a value on R&D. CHEMTECH 26(5): 46–50.

    CAS  Google Scholar 

  4. Struck, M.M. 1994. Biopharmaceutical R&D success: Rates and. development times. Bio/Technology 12: 674–677.

    CAS  Google Scholar 

  5. Bernstein, K. 1997. Is first best?. BioCentury 5(45): A1–A6.

    Google Scholar 

  6. Persidis, A. 1997. Industry Trends: Combinatorial chemistry. Nature Biotechnology 15: 479–480.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. vice president for business development at Argonex Inc., 2044 India Road, Suite 202, Charlottesville, VA, 22901

    Aris Persidis

  2. head of the biotechnology practice at Goldman, Sachs & Co., 85 Broad Street, New York, NY, 10004

    Garry E. Menzel

Authors
  1. Aris Persidis
    View author publications

    Search author on:PubMed Google Scholar

  2. Garry E. Menzel
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Persidis, A., Menzel, G. Biotechnology valuation. Nat Biotechnol 15, 813–814 (1997). https://doi.org/10.1038/nbt0897-813

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt0897-813

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing